IFNG and cancer: Inhibiting the MAPK or WNT signaling pathways prevents the upregulation of PD-L1 protein induced by EGF (epidermal growth factor) and IFN-γ, making cancer cells resistant to chemotherapy and conventional cancer treatments [239–241] (Fig. 6).